高级检索
当前位置: 首页 > 详情页

Radiomic signature as a predictive factor for lymph node metastasis in early-stage cervical cancer.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Dalian Medical University, Dalian, P.R. China [2]Cancer Hospital of China Medical University, Shenyang, P.R. China [3]Liaoning Cancer Hospital &Institute, Shenyang, P.R. China [4]CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, P.R. China [5]University of Chinese Academy of Sciences, Beijing, P.R. China [6]University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R.China
出处:
ISSN:

摘要:
Lymph node metastasis (LNM) is the principal risk factor for poor outcomes in early-stage cervical cancer. Radiomics may offer a noninvasive way for predicting the stage of LNM. To evaluate a radiomic signature of LN involvement based on sagittal T1 contrast-enhanced (CE) and T2 MRI sequences. Retrospective. In all, 143 patients were randomly divided into two primary and validation cohorts with 100 patients in the primary cohort and 43 patients in the validation cohort. T1 CE and T2 MRI sequences at 3T. The gold standard of LN status was based on histologic results. A radiologist with 10 years of experience used the ITK-SNAP software for 3D manual segmentation. A senior radiologist with 15 years of experience validated all segmentations. The area under the receiver operating characteristics curve (ROC AUC), classification accuracy, sensitivity, and specificity were used between LNM and non-LNM groups. A total of 970 radiomic features and seven clinical characteristics were extracted. Minimum redundancy / maximum relevance and support vector machine algorithms were applied to select features and construct a radiomic signature. The Mann-Whitney U-test and the chi-square test were used to test the performance of clinical characteristics and potential prognostic outcomes. The results were used to assess the quantitative discrimination performance of the SVM-based radiomic signature. The radiomic signatures allowed good discrimination between LNM and non-LNM groups. The ROC AUC was 0.753 (95% confidence interval [CI], 0.656-0.850) in the primary cohort and 0.754 (95% CI, 0584-0.924) in the validation cohort. A multiple-sequence MRI radiomic signature can be used as a noninvasive biomarker for preoperative assessment of LN status and potentially influence the therapeutic decision-making in early-stage cervical cancer patients. 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:304-310. © 2018 International Society for Magnetic Resonance in Medicine.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 医学
小类 | 2 区 核医学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 核医学
JCR分区:
出版当年[2019]版:
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
最新[2023]版:
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

影响因子: 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者:
第一作者机构: [1]Dalian Medical University, Dalian, P.R. China [2]Cancer Hospital of China Medical University, Shenyang, P.R. China [3]Liaoning Cancer Hospital &Institute, Shenyang, P.R. China
共同第一作者:
通讯作者:
通讯机构: [1]Dalian Medical University, Dalian, P.R. China [2]Cancer Hospital of China Medical University, Shenyang, P.R. China [3]Liaoning Cancer Hospital &Institute, Shenyang, P.R. China [4]CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, P.R. China [5]University of Chinese Academy of Sciences, Beijing, P.R. China [6]University of Electronic Science and Technology of China, Chengdu, Sichuan, P.R.China [*1]Department of Liaoning Cancer Hospital & Institute, No 44, Xiaoheyan Road, Shenyang, 110042, China [*2]Department of University of Electronic Science and Technology of China, Chengdu, Sichuan, China [*3]Department of CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, No 95, Zhongguancun East Road, Beijing 100190, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43370 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号